



Herbal Medicine in the Treatment of Alzheimer's Disease and Dementia: Phytoconstituent & Their Possible Pharmacological Activities

Shalaka V Dabhekar¹; Pranali A Chandurkar¹; Mayur B Kale¹; Nitu L Wankhede¹; Brijesh G Taksande¹; Milind J Umekar¹; Aman B Upaganlawar^{2*}

¹Shrimati Kishoritai Bhoyar College of Pharmacy Kamptee, Nagpur, Maharashtra, India.

²SNJB's Shriman Suresh Dada Jain College of Pharmacy, Neminagar, Chandwad, Nashik, Maharashtra, India.

*Corresponding Author(s): Aman B Upaganlawar

SNJB's Shriman Suresh Dada Jain College of Pharmacy,
Neminagar, Chandwad, Nashik, Maharashtra, India.

Email: amanrxy@gmail.com

Abstract

Alzheimer's Disease (AD) is a chronic, progressive neurological illness that is linked to ageing and is characterised by memory and cognition problems that progress to death. The pathogenicity is defined by tau protein hyperphosphorylation in neurons and the buildup of Amyloid-Beta Plaques (A β) and Neurofibrillary Tangles (NFT) in brain tissues, and the main cause is the oxidative stress-induced generation of Reactive Oxygen Species (ROS). There is no cure for Alzheimer's disease as of yet, while symptomatic treatment may have some potential for memory enhancement and other concerns associated with the disease, as well as being a preventative for some neurological disorders. Many natural products, such as medicinal plants and herbal remedies, have been used for the treatment of various memory disorders such as short-term memory loss, dementia, Alzheimer's, and Parkinson's disease for a long time, and a number of medicinal plants, either in their crude forms or as isolated compounds, have shown to reduce the pathological characteristics of the disease, and various studies have depicted the use of therapeutically derived medicinal plants. An attempt has been made in this review to clarify the molecular method of action of numerous plant extracts and phytochemicals that have been tested against AD.

Received: Jun 21, 2021

Accepted: Jul 27, 2022

Published Online: Jul 29, 2022

Journal: Depression and Anxiety: Open Access

Publisher: MedDocs Publishers LLC

Online edition: <http://meddocsonline.org/>

Copyright: © Upaganlawar AB (2022). *This Article is distributed under the terms of Creative Commons Attribution 4.0 International License*

Keywords: Alzheimer's disease; Dementia; Herbal medicines; Phytochemicals.

Introduction

Alzheimer's Disease (AD) is a severe, chronic, and progressive neurological illness that causes memory and cognition problems and eventually death [1,2]. A side from that, the etiology of Alzheimer's disease was unknown, although neuronal malfunction and cell death were the main events in these illnesses. Dementia is defined as a malfunction in the acquisition/learning, retention, or recall processes. Around 40 million

older people worldwide suffer from dementia [3,4]. Dementia affects an estimated 3.7 million senior citizens in India, and the prevalence is anticipated to double by 2030 and triple by 2050 [5]. Alzheimer's disease, Parkinson's disease, and epilepsy are all neurodegenerative illnesses that are linked to dementia. Excessive formation of Reactive Oxygen Species (ROS) is thought to play a crucial role in the pathogenesis of this disease, accord-



Cite this article: Upaganlawar AB, Dabhekar SV, Chandurkar PA, Kale MB, Wankhede NL, et al. Herbal Medicine in the Treatment of Alzheimer's Disease and Dementia: Phytoconstituent & Their Possible Pharmacological Activities. *Depress Anxiety Open Access*. 2022; 1(1): 1002.

ing to a growing body of research. Dementia affects 24 million people worldwide, and the number is expected to rise every 20 years until 2040 [6]. After the age of 65, it is thought that the risk of developing AD doubles every five years [7,8]. Due to the lack of a cure for dementia and Alzheimer's disease, the public health priority has recently shifted to the prevention of cognitive decline. Although it is still unclear which variables cause the molecular cascade of neurodegeneration in Alzheimer's disease, environmental factors, vascular pathology, and risk factors have recently been revealed to play a key part in the disease's pathogenesis [9]. As a result, lifestyle interventions that benefit neurodegeneration and vascularity, such as natural nutrition and nutritional supplements, cognitive and social activity, and physical activity, have been identified as potential target alternatives for AD prevention [9,10,11,12].

Furthermore, there is strong evidence that a diet rich in specific nutritional food groups (fruit, fish, and vegetables) can reduce the occurrence and prevalence of some of the most common clinical outcomes, including neurodegenerative disorders, cardiovascular diseases, diabetes, cancer, and a variety of other conditions [13,14,15]. These specialised nutritional food groups are high in micronutrients and vitamins, which De Felice described as nutraceuticals in 1989 because of their nutritional characteristics while also being beneficial to health (like medications) [16]. Preventive or protective agents, such as nutraceuticals derived from natural products or herbal prescriptions, are also being employed, and their market is rising, which is directly related to therapeutic efficacy in the prevention of AD.

Meanwhile, herbal plants such as *Centella asiatica*, *Ginkgo biloba*, *Withania somnifera*, *Bacopa monnieri*, *Salvia officinalis*, *Melissa officinalis*, *Tinospora cordifolia*, *Glycyrrhiza glabra*, *Panax Ginseng* Extract, and others contain active molecules that are responsible for the prevention of certain brain disorders and associated co-morbidities. The current state of Alzheimer's disease has necessitated a crucial need to improve our understanding of neurodegeneration causation and to develop novel techniques for preventing neuronal diseases [17]. Through the onset of progressive neuronal cell death and oxidative cellular degeneration, genetic and environmental variables played a major role in the pathophysiology of these illnesses.

Sign and symptoms

Alzheimer's disease is marked by memory loss, which manifests itself in behaviours such as forgetting appointments, being away from home, misplacing items, and asking the same questions over and over. Insomnia, anxiety, sadness, disruptive behaviour, and hallucinations are all symptoms of Alzheimer's disease, in addition to memory impairments [18]. Chronic dementia accounts for almost 60% to 70% of instances of Alzheimer's disease [19].

Several investigations have discovered evidence that AD is caused or exacerbated by decreased brain metabolic activity. Each stage of Alzheimer's disease has its own set of symptoms [20].

✓ **Stage One:** It lasts two to four years on average. Confusion, amnesia, disorientation, recent memory loss, and mood changes are all symptoms.

✓ **Stage Two:** This stage usually lasts two to 10 years. Reduced memory, reduced attention span, hallucinations, restlessness, muscle spasms, increased anger, and increased inability to organise thoughts are all common symptoms.

✓ **Stage Three:** It lasts one to three years and is characterised by incontinence, swallowing difficulties, the development of skin infections, and seizures.




Figure 1: Clinical Symptoms of Alzheimer Disease.

Etiopathogenesis

In the progression of AD, synaptic loss or dysfunction, reduced neuronal metabolism, and the loss of numerous neurotransmitter systems are all seen [21]. Senile plaques made up of Amyloid-Beta ($A\beta$) deposits and Neurofibrillary Tangles (NFT) made up of aggregated tau proteins are the two neuropathological hallmarks of Alzheimer's disease. These plaques form as a result of abnormal processing of amyloid precursor protein, resulting in an overproduction of β -amyloid protein. The neuronal degeneration seen in Alzheimer's disease is caused by the formation of neurofibrillary tangles and amyloid plaques. Furthermore, oxidative stress, metal ion dyshomeostasis, mitochondrial dysfunction, neuroinflammation, autophagy, Endoplasmic Reticulum (ER) dysfunction, cell cycle dysregulation, and decreased levels of the neurotransmitter acetylcholine are thought to play a role in Alzheimer's disease progression which have been implicated in the aetiology of Alzheimer's disease [22,23,24].

Some recent research has revealed that epigenetic control may play a role in the progression and progression of Alzheimer's disease [25]. Although the pathophysiology of Alzheimer's disease is still unknown, it is clear that multiple factors are involved.




Figure 2: Pathophysiology of Alzheimer Disease (AD).

Herbal plants used in the treatment of alzheimer's disease and dementia

In a number of preclinical and human trials, medicinal plants such as *Salvia officinalis*, *Melissa officinalis*, *Rosmarinus officinalis*, and others have been cited for their cholinergic actions and memory-enhancing properties [26]. Ayurveda has already contributed a number of lead molecules to medicine devel-

opment, with many of them currently undergoing clinical trials [27]. Plants and their extracts have been found to protect against Parkinson's Disease (PD) [28], Huntington's Disease (HD) [29], ADHD [30], Multiple Sclerosis (MS) [31], schizophrenia [32], stroke [33], etc.

Recently, medicinal plants have gained wide acceptance because of their fewer side effects compared to synthetic medicines and the necessity to meet the requirements of medicine for an increasing human population suffering from various neurodegenerative disorders. Among all those, several investigations have reported that medicinal plants are utilised in Alzheimer's disease treatment, which includes *Serrate clubmoss*, *Centella asiatica*, *Ginkgo biloba*, *Withania somnifera*, *Bacopa monnieri*, *Salvia officinalis*, *Melissa officinalis*, *Tinospora cordifolia*, *Glycyrrhiza glabra*, and many more.




Figure 3: Possible mechanism of action of herbal drugs.

Ashwagandha (*Withania somnifera*)

It is a member of the Solanaceae family, and its root is commonly used for medicinal purposes. A prior study found that ashwagandha possesses cholinergic action [34]. The potential of ashwagandha to boost acetylcholine levels in the brain contributes to its memory-enhancing and cognition-improving properties. According to molecular modelling research, withanamides A and C bind to A β and prevent fibril formation [35]. It was also discovered that withanamides prevented amyloid plaques from damaging activated neuronal cells [35,36,37]. In human neuroblastoma cells, ashwagandha methanol extract stimulated the growth and development of the neural network [38]. In verified AD mice, per-oral administration of *Withania* root extract reversed behavioural deficits and prevented the formation of A β plaque [39]. The overexpression of the low-density lipoprotein receptor-related protein in the liver has been connected to Ashwagandha's effects [39]. The roots of ashwagandha help the body's defensive mechanism in cases of chronic disease by enhancing cellular immunity and neutralising the cytotoxic cascade's fatal mediators, such as cytokines and ROS [40,41].

Turmeric (*Curcuma longa*)

It is a member of the Zingiberaceae family. Because of its anti-amyloidogenic, antioxidant, and anti-inflammatory properties, it is used in the treatment of AD [42]. Turmeric plant extracts have been shown to reduce the production of fibrils and A β aggregation in experimental rats [43]. The results of the study also revealed a decrease in oxidative stress and an

improvement in cognitive functions. It helps to prevent plaque buildup in the brain. Turmeric reduces oxidative stress and the formation of amyloid plaques [44]. In one study, low dosages of turmeric lowered A β levels by up to 40% in animals with AD when compared to a control medication [43].

Turmeric reduced the plaque formation in the brains of mice with Alzheimer's disease by 43% when given in low dosages [44]. According to a prior study, low doses of turmeric given over a lengthy period of time are more helpful than greater doses in the treatment of AD [45,46]. These effects, according to the researchers, aid in the treatment of Alzheimer's symptoms associated with inflammation and oxidation [47]. By accumulating cholesterol esters intracellularly, hypercholesterolemia and hyperlipidemia create amyloid plaques [48]. According to researchers, curcumin may have beneficial property for Alzheimer's by blocking cholesterol production and lowering serum peroxides [49].

Shankpushpi (*Convolvulus pluricaulis*)

It is a member of the Convolvulaceae family. A prior study found that extracts of *Convolvulus pluricaulis* in aqueous and ethyl acetate improved memory and learning capacities [50]. Shankpushpi is used in India as a nervine stimulant to improve memory and cerebral function in various formulations [51,52,53,]. Another study found that a wide range of secondary metabolites, including steroids, anthocyanins, flavonol glycosides, and triterpenoids, are responsible for memory-improving and nootropic properties [52]. It is thought to relax nerves by controlling the body's stress hormone synthesis (cortisol and adrenaline) [54].

Ethanol extract of shankpushpi, as well as its aqueous and ethyl acetate fractions, dramatically improved memory retention and learning capacities in rats [55]. Similarly, giving aged mice shankpushpi for a week improved their memory [56]. Shankpushpi administration enhanced acetylcholinesterase activity in the hippocampus CA1 and CA3 areas, which are connected with memory function and learning capacities [57]. Shankpushpi metabolites have nootropic and memory-enhancing properties, as well as boost pharmacological activity [58]. In rats, ethanol extract of shankpushpi and its fractions (ethyl acetate and aqueous) significantly improve learning and memory [55]. Much research has shown that administering *Convolvulus pluricaulis* extracts improves memory in older mice and improves retention and spatial learning performance in newborn rat pups, suggesting memory-upgrading.

Ginkgo (*Ginkgo biloba*)

It is a member of the Ginkgoaceae family. This is a natural medicinal plant whose leaves are used to treat Alzheimer's patients with cognitive impairment [59]. It contains bilobalide, a neuroprotective compound [60]. It reduces free radicals and enhances memory in Alzheimer's patients [61]. It contains flavonoids, which are known to help with memory [62]. *Ginkgo biloba* protects against corticosteroid-induced neurodegeneration in the hippocampus and GABA inhibitory neurotransmission [63]. Administration of Ginkgo significantly improved memory and learning performance in albino rats [64]. Scientific research proved that *Ginkgo biloba* has the potential to improve cognitive function for the treatment of AD patients. *Ginkgo biloba* extract is extensively employed in treating patients with numerous forms of dementia in Europe [65,66].

Gotu kola (*Centella asiatica*)

It is a member of the Apiaceae family. Saponins are the main components of Gotu Kola. It's widely used to cleanse the blood, improve memory, lower blood pressure, and extend life. It aids in the relaxation of the mind and the release of tension. Gotu kola aqueous extracts are used in ayurveda to rejuvenate and restore brain cells, as well as to alleviate sleeplessness [67].

Furthermore, in vitro data reveals that Gotu Kola is effective in inhibiting the β -amyloid cell, implying that it is useful in the treatment of β -amyloid poisoning in Alzheimer's patients [68]. [139] found that, in Wistar rat treatment with *Centella asiatica* (Linn) fresh leaf extract improved learning ability and memory retention capability. Depression, rheumatism, mental weakness, abdominal discomfort, and epilepsy are all treated with it [69]. It was also found that *Centella asiatica* decreased oxidative stress response and reversed A β pathology [70].

Jyotishmati (*Celastrus paniculatus*)

It belongs to the family Celastraceae. It prevented neuronal cell damage from hydrogen peroxide toxicity due to its antioxidant activity [71]. Administration of Jyotishmati prevents neuronal cell damage caused by glutamine-induced toxicity [72]. It increases cholinergic activity, which contributes to its ability to improve memory performance [73]. Jyotishmati aqueous extract has antioxidant and cognition-enhancing properties [74]. Jyotishmati extracts protect neuronal cells against hydrogen peroxide induced toxicity in part by virtue of their antioxidant and free radical scavenging activities [75]. The cholinergic activity of Jyotishmati seed aqueous extract was observed in a dose-dependent manner thereafter, refining memory activity [76].

Liquorice (*Glycyrrhiza glabra*)

It is a member of the Fabaceae family and contains coumarins, isoflavonoids, saponins, flavonoids, and stilbenoids, which are used to treat Alzheimer's disease [77]. Gastric ulcers, lung congestion, hoarseness, and throat difficulties are all treated by liquorice [78]. Liquorice has been shown to improve memory in scopolamine-induced dementia [79]. Liquorice has been shown to improve memory in mice by [80]. Another study found that giving a 1-month-old albino rat orally fed *Glycyrrhiza glabra* plant extract for 6 weeks increased memory and learning capacity [81]. Furthermore, a study found that *Glycyrrhiza inflata* extract, a distinct species of glycyrrhiza, strongly reduced A β aggregation and radical-scavenging activities [82].

Spikenard (*Nardostachys jatamansi*)

It is a member of the Caprifoliaceae family. It is a medicinally important plant that is highly regarded in Ayurveda. The rhizome, or root, which has medicinal properties, is the most important portion of the spikenard. It contains coumarins and sesquiterpenes of various sorts. *Nardostachys jatamansi* was found to improve memory retention and learning in both old and young mice, as well as reverse scopolamine and diazepam-induced amnesia in research. It also helped to cure amnesia caused by ageing [83]. It was found that *Nardostachys jatamansi* to be effective in preventing stress-induced memory loss [84].

Ginseng (*Panax ginseng*)

It is a member of the Araliaceae family. A previous study discovered that ginseng consumption improves learning ability in mice. In vivo and in vitro research has demonstrated the effi-

cacy of ginseng powder, extract, and different ginsenosides on AD [85,86,87]. Ginseng is an herb that has been used to treat Alzheimer's disease. It's a popular memory and energy-boosting plant in China, Japan, and Korea. Ginseng, also known as Chinese ginseng, contains phytochemicals such as ginsenosides (saponins), a triterpenoid dammarane derivative, and 20(S)-protopanaxadiol, which inhibits Amyloid-Beta (A β) aggregation, removes A β from neurons, increases neurotrophic factor secretion, and improves mitochondrial dysfunction [88].

According to a molecular enzyme study, ginsenosides contained in ginseng have significant AChE inhibitory activity, which is an efficient strategy for lowering AD symptoms [89]. Through the stimulation of phosphatidic acid receptors involved in hemolysis, Gintonin, a bioactive glycoprotein, lowers the production of A β and increases learning and memory capacity [90]. It also reduces the symptoms of Alzheimer's disease by stimulating autophagy, anti-inflammatory mechanisms, anti-apoptosis, and oxidative stress management, as evidenced by significant in vitro and in vivo research [91].

The significance of gintonin in the treatment of Alzheimer's disease has been scientifically demonstrated for many years; it modulates G protein-coupled lysophosphatidic acid receptors, altering the cholinergic system and neurotrophic factors, resulting in a reduction in plaque formation. Gintonin treatment reduced memory impairment in mice by reducing A β plaque deposition and increasing the release of According to research, treatment with Gintonin reduced memory impairment in mice by reducing A β plaque deposition and increasing the release of A β PP α in the body [92].

In an Alzheimer's disease mice model, gintoninis believed to have the ability to boost choline acetyltransferase expression, prompting the release of Ach, and therefore attenuating A β caused cholinergic dysfunction [93]. Because of the presence of stigmasterol, β -sitosterol, and linoleic acid in red ginseng, it protects against A β 25–35-induced damage by suppressing NF- κ B and MAPK pathway-mediated apoptosis and inflammation in the body [92]. The red oil and nonsaponin polysaccharide fractions worked together to decrease pro-inflammatory mediators by downregulating the p38/-JNK/-NF- κ B pathway, as well as the caspase-3/PARP-1 signalling pathway, which inhibited mitochondria-mediated apoptosis and protected against A β -induced damage [88].

Nutmeg (*Myristica fragrans*)

It is a member of the Myristicaceae family. It's used to treat mental disorders, digestive problems, leukaemia, body aches, vomiting, tachycardia, dizziness, and memory problems [94]. It has antidepressant, antioxidant, and antibacterial properties [95]. Nutmeg N-hexane extract was given orally to young and old mice at three dose levels (5, 10 and 20 mg/kg p.o.) for three days. At 5 mg/kg, this medication was found to be helpful in reversing scopolamine and diazepam-induced learning and memory deficits. This study established the efficacy of *Myristica fragrans* in the treatment of AD and memory loss [96].

Guduchi (*Tinospora cordifolia*)

It is a member of the Menispermaceae family and has memory-enhancing qualities in both normal and memory-deficient animals. Choline supplementation improves cognitive performance by stimulating the immune system and enhancing acetylcholine production. It is known as a learning and memory booster in Ayurveda. The use of an aqueous extract of guduchi

roots improved verbal learning and logical memory [97].

Brahmi (*Bacopa monnieri*)

It is a member of the Scrophulariaceae family. It has multiple branches with oblong leaves that have decreased in size and purple flowers. Saponins and triterpenoid bacosaponins are the primary components [98]. Traditional healers combine Brahmi with *Centella asiatica* and *Evolvulus alsinoides* to treat memory problems and Alzheimer's disease [99]. It improves memory in Alzheimer's patients. It has adaptogenic, neuroprotective, anti-bacterial, and memory-improving properties [100].

The efficacy of brahmi on cognitive performance, anxiety, and depression in the elderly has been recorded, and it has been found to be useful in improving cognitive functioning in the elderly. This research backs up the use of it as a memory booster. It has long been used to improve neuropharmacological and nootropic actions as well as memory and cognitive function [101,102,103]. They protect cortical, hippocampal, and striatal neurons in the brain from DNA-linked dysfunction and neurotoxicity in AD. In rats with AD-like symptoms, *Bacopamonnieri* has been shown to reduce cholinergic degeneration and improve cognition [104].

Maca (*Lepidium meyenii*)

It is a member of the Brassicaceae family, and it has been shown to increase memory and learning capacities [105]. In Alzheimer's sufferers, maca showed memory-boosting properties. It boosts acetylcholine levels, which improves memory [106]. Because of its acetylcholinesterase inhibitory and antioxidant properties, it improves experimental memory impairment caused by ovariectomy. The potential of *Lepidium meyenii* to improve memory retention and learning capacities in ovariectomized mice was discovered, and this activity may be attributed, at least in part, to its ability to lower lipid peroxidation and ace-

tylcholinesterase in ovariectomized mice [107].

Drumstick tree (*Moringa oleifera*)



It is a member of the Moringaceae family. Its leaf extract contains antioxidant vitamins C and E, which help to improve cognition in Alzheimer's patients [108]. It contains nootropic properties and can help with stress in Alzheimer's patients (Mohan *et al.*, 2005). It affects monoamines, which have a role in memory [109]. According to a rat study, *Moringa oleifera* reduces the severity of colchicine-induced AD via altering monoamine levels such as norepinephrine, dopamine, and serotonin [110].

Amla (*Emblica officinalis*)







It is a member of the Euphorbiaceae family. In a dose-dependent manner, it showed a considerable improvement in memory retention in young and old rats. It has an important function in the treatment of memory deficits and AD as a memory enhancer and reversal of memory deficiencies [111].

In a study, the memory-enhancing effect of piracetam when combined with amla and turmeric against aluminum-induced cognitive impairment and oxidative damage in rats was investigated. For six weeks, rats were administered 100 mg/kg of aluminium chloride orally. Rats were given amla (100 mg/kg, p.o.), curcumin (100 mg/kg, p.o.), and piracetam (200 mg/kg, i.p.) at the same time for 6 weeks. On days 21 and 42 of therapy, memory was assessed using elevated plus maze task paradigms and Morris water maze tests. Rats were slaughtered on day 43 of treatment to determine the amount of oxidative damage. In rats treated with *Emblica officinalis* (100 mg/kg, p.o.), curcumin (100 mg/kg, p.o.), and piracetam (200 mg/kg, i.p.), oxidative stress was greatly reduced and memory was significantly improved compared to rats treated solely with piracetam (200 mg/kg, i.p.). Amla could be used to treat memory loss, it has an antioxidant and memory enhancer properties [112].




Table 1: Medicinal Plants Used in Alzheimer Disease and Dementia.

Plant name	Biological source	Phytoconstituents	Mechanism of action	References
<p>Ashwagandha</p> 	<i>Withania somnifera</i>	withanamides A and withanamides C	B-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) and Acetylcholinesterase are Effectively Inhibited (AChE).	[113].
<p>Coriander</p> 	<i>Coriandrum sativum</i>	Coumarin	Aβ42, glial cell proliferation, and extracellular signal-regulated kinase activation are all inhibited by this compound. Reduces oxidative stress in the rat hippocampus, which improves Aβ (1-42)-induced spatial memory impairment.	[114].

<p>Ginseng</p> 	<p><i>Panax ginseng</i></p>	<p>Ginsenoside</p>	<p>Cholinergic and activates Rb1, Rg 1-3, Re, and Rh2 effective in the treatment of AD.</p>	<p>[115].</p>
<p>Coffea</p> 	<p><i>Coffea arabica</i></p>	<p>Caffeine and chlorogenic acids</p>	<p>Possesses neuroprotective effect in alleviating AD.</p>	<p>[61].</p>
<p>Liquorice</p> 	<p><i>Glycyrrhiza glabra</i></p>	<p>Glycyrrhizin</p>	<p>In mice, it alleviates the neuroinflammation and memory impairment caused by systemic lipopolysaccharide therapy.</p>	<p>[116]</p>
<p>Magnolia-bark</p> 	<p><i>Magnolia officinalis</i></p>	<p>Magnolol and honokiol</p>	<p>The ability of AChE inhibition may be connected to the ability to recover memory impairment caused by scopolamine. Reduces Aβ-induced cell death, is neuroprotective, reduces ROS production, inhibits caspase-3 activity, and suppresses intracellular calcium.</p>	<p>[117,118].</p>
<p>Ginger</p> 	<p><i>Zingiber officinale</i></p>	<p>Shogaol and gingerol</p>	<p>Significantly enhances rates of learning and memory.</p>	<p>[119].</p>
<p>Saffron</p> 	<p><i>Crocus sativus</i></p>	<p>Crocin</p>	<p>It reduces cognitive deterioration in Alzheimer's patients. Inhibits Aβ and improves cognitive function in Alzheimer's patients.</p>	<p>[120,121].</p>
<p>Maca</p> 	<p><i>Lepidium meyenii</i></p>	<p>Choline</p>	<p>In ovariectomized (OVX) mice, it improves learning and memory while lowering lipid peroxidation and acetylcholinesterase.</p>	<p>[107].</p>

<p>Ginkgo</p> 	<p><i>Ginkgo biloba</i></p>	<p>Bilobalideginkgolide</p>	<p>In mice, it promotes cell proliferation and neuroblast differentiation. Effective for the treatment and prevention of AD.</p>	<p>[61, 122].</p>
<p>Fig</p> 	<p><i>Ficus carica</i></p>	<p>Quercetin</p>	<p>Promotes neuronal bioactivity and protects against oxidative stress-related AD. Cognitive and behavioural deficiencies are improved.</p>	<p>[123,124].</p>
<p>Malkangani</p> 	<p><i>Celastrus paniculatus</i></p>	<p>Celapanin and celapanigin</p>	<p>Increasing ACh levels in the rat brain increases cholinergic activity and improves memory performance. Protects embryonic rat forebrain neuronal cells from glutamine-induced neurotoxicity.</p>	<p>[71,73].</p>
<p>Turmeric</p> 	<p><i>Curcuma longa</i></p>	<p>Curcumin</p>	<p>It inhibits the development of Aβ oligomer and fibril in the brains of Tg2576 mice. Reduces the astrocytic marker GFAP, Aβ, and plaque burden in Alzheimer transgenic mice.</p>	<p>[125,45].</p>
<p>Amur grape</p> 	<p><i>Vitis amurensis</i></p>	<p>Amurensis</p>	<p>In cultures of rat cortical neurons, it prevents neuronal death and has antioxidant properties. In AD mouse models, it improves learning and memory.</p>	<p>[126].</p>
<p>Indian tulip tree</p> 	<p><i>Thespesia populnea</i></p>	<p>Gossypol</p>	<p>It inhibits the activity of AChE. In diazepam and scopolamine AD mouse models, it improves learning and memory.</p>	<p>[127].</p>

<p>Pomegranate</p> 	<p><i>Punica granatum</i></p>	<p>Polyphenols</p>	<p>In transgenic mice, it reduces Aβ 42 accumulation and amyloid deposition in the hippocampus, protects PC12 cells from H₂O₂ generated oxidative stress, improves cognitive performance, and suppresses cell death caused by Aβ produced oxidative stress.</p>	<p>[128,129].</p>
<p>Brahmi</p> 	<p><i>Bacopa monnieri</i></p>	<p>brahmine, nicotine, herpestine, bacosides A and B</p>	<p>Antioxidant, nootropic, rejuvenation, inhibits acetylcholinesterase</p>	<p>[100,130].</p>
<p>Shankpushpi</p> 	<p><i>Convolvulus pluricaulis</i></p>	<p>alkaloids, glycosides, flavonoids, carbohydrates, proteins, sterols, gum and mucilages</p>	<p>Nootropic, anxiolytic, tranquilizing, antidepressant, anti-stress, anti-amnesic</p>	<p>[131].</p>
<p>Jatamansi</p> 	<p><i>Nardostachys jatamansi</i></p>	<p>sesquiterpenes and coumarins</p>	<p>AChE inhibitor, antioxidant, memory enhancer, anti-inflammatory properties</p>	<p>[132].</p>
<p>Mandookaparni</p> 	<p><i>Centella asiatica</i></p>	<p>madecassoside, asiaticoside, madecassic acid and asiatic acid</p>	<p>Modulates antioxidant and mitochondrial pathways and improves cognitive function</p>	<p>[133].</p>
<p>Guggul</p> 	<p><i>Commiphora whighitti</i></p>	<p>Z-guggulsterone, E-guggulsterone, Z-guggulsterol and guggulsterol I-V</p>	<p>Anti-inflammatory efficiency, learning and memory enhancer</p>	<p>[134].</p>
<p>Amla</p> 	<p><i>Emblica officinalis</i></p>	<p>Phenolic compounds, amino acids, tannins, alkaloids, and carbohydrates</p>	<p>Memory enhancer</p>	<p>[127].</p>

<p>Giloy</p> 	<p><i>Tinospora cordifolia</i></p>	<p>Choline, Tinosporin, Isocolumbin, Palmatine</p>	<p>Anti-amyloidogenic, anti-cholinesterase, antioxidant, neuroprotective effects, nootropic ameliorates cognitive deficits associated with glutamate-induced excitotoxicity</p>	<p>[135,136].</p>
<p>Lemon Balm</p>  <p>shutterstock.com · 1416489347</p>	<p><i>Melissa officinalis</i></p>	<p>Citronellol, caryophyllene, neral, geraniol, geranyl acetate and citronellal</p>	<p>Nootropic, anxiolytic, antidepressant, anti-stress, anti-amyloid</p>	<p>[137,138].</p>
<p>Nutmeg</p> 	<p><i>Myristica fragrans</i></p>	<p>Myristicin</p>	<p>Acetylcholinesterase inhibitors, memory-enhancing effect, antioxidant, anti-inflammatory</p>	<p>[96].</p>

Conclusion

In this study, we went over the management of AD in greater depth, as well as medicinal herbs with possible therapeutic benefit. Despite the vast amount of information available about this complex condition, there is no complete solution other than symptomatic treatment. As a result, herbal therapy is expected to slow the progression of Alzheimer's disease and alleviate its symptoms. Patients with Alzheimer's disease and memory problems may benefit from herbal therapy. There is a lot of research going on around the world to find an effective treatment for Alzheimer's disease. According to this study, herbal therapy appears to be a promising option for treating Alzheimer's disease. The majority of herbs and plants have been chemically analysed, and some are currently undergoing clinical trials. The end product is gorgeous and significant. The fundamental mechanisms of action, on the other hand, are still being discovered. Herbs may have a promising function in the early treatment of AD and other dementia-related disorders. One of the main advantages is that, as compared to pharmaceutical drugs, they have low toxicity. The use of various herbal products is becoming increasingly popular. Because multiple studies have shown that using synthetic medications has negative side effects, there is a need for an alternate source of drugs with minimal or no side effects. This article discusses the function of medicinal plants in the treatment of Alzheimer's disease. The mechanisms of action, on the other hand, are still unknown.

Future scope

Alternative medicine has been used since ancient times, and several extracts of medicinal plants and herbal combinations have shown promise in the treatment of Alzheimer's disease. Pharmacologically active phytoconstituents should be extracted, identified, and carefully tested. Multicenter clinical trials should be conducted to evaluate the effectiveness of these herbal drugs alone or in the form of formulations for the treatment of Alzheimer's disease. The use of herbal remedies in the treatment of AD should be compared to the present phar-

macological treatment. In order to strengthen the clinical trial's validation, such research should include the identification of the active principle. More large-scale, multicenter research is needed to assess the usefulness of these drugs in the cognitive degeneration of AD. Until then, this review provides some information about the efficacy of a variety of herbs in the treatment of Alzheimer's disease.

References

1. Mancuso C, Scapagnini G, Currò D, Stella AMG, De Marco C, et al. Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. *Frontiers in Bioscience-Landmark*. 2007; 12: 1107-1123.
2. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, et al. Pleiotropic protective effects of phytochemicals in Alzheimer's disease. *Oxidative Medicine and Cellular Longevity*. 2012; 2012.
3. Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer's disease. *Signal transduction and targeted therapy*. 2019; 4: 1-22.
4. Prince M. Epidemiology of dementia. *Psychiatry*. 2007; 6: 488-490.
5. Rosow K, Holzapfel A, Karlawish JH, Baumgart M, Bain LJ, et al. Countrywide strategic plans on Alzheimer's disease: Developing the framework for the international battle against Alzheimer's disease. *Alzheimer's & Dementia*. 2011; 7: 615-621.
6. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. *Cold Spring Harbor perspectives in medicine*. 2012; 2: p.a006239.
7. Di Carlo A, Baldereschi M, Amaducci L, Lepore V, Bracco L, et al. Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study. *Journal of the American Geriatrics Society*. 2002; 50: 41-48.
8. Bermejo Pareja F, Benito León J, Vega S, Medrano MJ, Roman GC, et al. Neurological Disorders in Central Spain (NEDICES) Study Group. Incidence and subtypes of dementia in three elderly populations of central Spain. *Journal of the neurological*

- sciences. 2008; 264: 63-72.
9. Polidori MC, Pientka L, Mecocci P. A review of the major vascular risk factors related to Alzheimer's disease. *Journal of Alzheimer's Disease*. 2012; 32: 521-530.
 10. Brown WJ, Basil MD. Parasocial interaction and identification: Social change processes for effective health interventions. *Health communication*. 2010; 25: 601-602.
 11. Polidori MC, Schulz RJ. Nutritional contributions to dementia prevention: Main issues on antioxidant micronutrients. *Genes & nutrition*. 2014; 9: 1-11.
 12. John Ogbodo, Chinazom Agbo, Ugochi Njoku, Martins Ogugorfor, Simeon Egba, et al. Alzheimer's disease: Pathogenesis and Therapeutic interventions, *Current Aging Science*. 2021; 21: 1-25.
 13. Panza F, Solfrizzi V, Colacicco AM, D'introno A, Capurso C, et al. Mediterranean diet and cognitive decline. *Public health nutrition*. 2004; 7: 959-963.
 14. Sofi F, Cesari F, Abbate R, Gensini GF, Casini A, et al. Adherence to Mediterranean diet and health status: Meta-analysis. *Bmj*. 2008; 337.
 15. Frisardi V, Solfrizzi V, Seripa D, Capurso C, Santamato A, et al. Metabolic-cognitive syndrome: a cross-talk between metabolic syndrome and Alzheimer's disease. *Ageing research reviews*. 2010; 9: 399-417.
 16. Kalra EK, et al. Nutraceutical-definition and introduction. *Aaps Pharmsci*. 2003; 5: 27-28.
 17. Postuma RB, Gagnon JF, Vendette M, Montplaisir JY. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. *Brain*. 2009; 132: 3298-3307.
 18. Singhal AK, Naithani V, Bangar OP. Medicinal plants with a potential to treat Alzheimer and associated symptoms. *International Journal of Nutrition, Pharmacology, Neurological Diseases*. 2012; 2: 84.
 19. Burns A, Iliffe S. Alzheimer's disease. *BMJ* 338, b158. Go to original source... Go to PubMed. 2009.
 20. Kuller LH. Hormone replacement therapy and its potential relationship to dementia. *Journal of the American Geriatrics Society*. 1996; 44: 878-880.
 21. Guo T, Zhang D, Zeng Y, Huang TY, Xu H, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. *Molecular neurodegeneration*. 2020; 15: 1-37.
 22. Michalska P, León R. When it comes to an end: Oxidative stress crosstalk with protein aggregation and neuroinflammation induce neurodegeneration. *Antioxidants*. 2020; 9: 740.
 23. Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. *Nature Reviews Neuroscience*. 2019; 20: 148-160.
 24. Ogbodo Onyebuchi John, Ihim Stella Amarachi, Agbo Precious Chinazom, Echezona Aadaeze, Mayur B Kale, et al. Phytotherapy: A promising approach for the treatment of Alzheimer's disease. *Pharmacological Research - Modern Chinese Medicine*. 2022; 2: 100030.
 25. Chouliaras L, Rutten BP, Kenis G, Peerbooms O, Visser PJ, et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. *Progress in neurobiology*. 2010; 90: 498-510.
 26. Kennedy DO, Scholey AB. The psychopharmacology of European herbs with cognition-enhancing properties. *Current pharmaceutical design*. 2006; 12: 4613-4623.
 27. Jachak SM, Saklani A. Challenges and opportunities in drug discovery from plants. *Current science*, 2007; 1251-1257.
 28. Houghton PJ, Howes MJ. Natural products and derivatives affecting neurotransmission relevant to Alzheimer's and Parkinson's disease. *Neurosignals*. 2005; 14: 6-22.
 29. Varshney M, Kumar B, Rana VS, Sethiya NK. An overview on therapeutic and medicinal potential of poly-hydroxy flavone viz. Heptamethoxyflavone, Kaempferitrin, Vitexin and Amentoflavone for management of Alzheimer's and Parkinson's diseases: A critical analysis on mechanistic insight. *Critical Reviews in Food Science and Nutrition*. 2021; 1-24.
 30. Pellow J, Solomon EM, Barnard CN. Complementary and alternative medical therapies for children with Attention-Deficit/Hyperactivity Disorder (ADHD). *Alternative Medicine Review*. 2011; 16: 323.
 31. Brady CM, Das Gupta R, Dalton C, Wiseman OJ, Berkley KJ, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. *Multiple Sclerosis Journal*. 2004; 10: 425-433.
 32. Ahmed M, Azam K, Nur M. Traditional knowledge and formulations of medicinal plants used by the traditional medical practitioners of Bangladesh to treat schizophrenia like psychosis. *Schizophrenia Research and Treatment*. 2014; 2014.
 33. Chun HS, Kim JM, Choi EH, Chang N. Neuroprotective effects of several Korean medicinal plants traditionally used for stroke remedy. *Journal of Medicinal food*. 2008; 11: 246-251.
 34. Schliebs R, Liebmann A, Bhattacharya SK, Kumar A, Ghosal S, et al. Systemic administration of defined extracts from *Withaniasomnifera* (Indian Ginseng) and *Shilajit* differentially affects cholinergic but not glutamatergic and GABAergic markers in rat brain. *Neurochemistry International*. 1997; 30: 181-190.
 35. Jayaprakasam B, Padmanabhan K, Nair MG. Withanamide in *Withaniasomnifera* fruit protect PC 12 cells from β amyloid responsible for Alzheimer's disease. *Phytotherapy Research*. 2010; 24: 859-863.
 36. Dhuley JN. Effect of ashwagandha on lipid peroxidation in stress-induced animals. *Journal of ethnopharmacology*. 1998; 60: 173-178.
 37. Parihar MS, Hemnani T. Phenolic antioxidants attenuate hippocampal neuronal cell damage against kainic acid induced excitotoxicity. *Journal of biosciences*. 2003; 28: 121-128.
 38. Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M, et al. Axon-or dendrite-predominant outgrowth induced by constituents from *Ashwagandha*. *Neuroreport*. 2002; 13: 1715-1720.
 39. Sehgal A, Kumar M, Jain M, Dhawan DK. Piperine as an adjuvant increases the efficacy of curcumin in mitigating benzo (a) pyrene toxicity. *Human & experimental toxicology*. 2012; 31: 473-482.
 40. Abbas SS, Singh N. *Anti-stress Agents (Herbs) of Indian Origin-Herbal Drugs, A twenty first century perspective*. Delhi: Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization (DRDO), Govt. of India. 2006; 578-591.
 41. Ven Murthy MR, Ranjekar KP, Ramassamy C, Deshpande M. Scientific basis for the use of Indian ayurvedic medicinal plants in the treatment of neurodegenerative disorders: 1. *Ashwagandha*. *Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents)*. 2010; 10: 238-246.
 42. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegen-

- erative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. The international journal of biochemistry & cell biology. 2009; 41: 40-59.
43. Shytle RD, Bickford PC, Rezai zadeh K, Hou L, Zeng J, Tan J, et al. Optimized turmeric extracts have potent anti-amyloidogenic effects. Current Alzheimer Research. 2009; 6: 564-571.
 44. Mishra S, Palanivelu K. The effect of curcumin (turmeric) on Alzheimer's disease: An overview. Annals of Indian Academy of Neurology. 2008; 11: 13.
 45. Yang F, Lim GP, Begum AN, Ubada OJ, Simmons MR, Ambegao-kar SS, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Journal of Biological Chemistry. 2005; 280: 5892-5901.
 46. Reinke AA, Gestwicki JE. Structure–activity Relationships of amyloid beta aggregation inhibitors based on curcumin: Influence of linker length and flexibility. Chemical biology & drug design. 2007; 70: 206-215.
 47. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, et al. Phenolic anti-inflammatory antioxidant reversal of A β -induced cognitive deficits and neuropathology. Neurobiology of aging. 2001; 22: 993-1005.
 48. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid β peptides. Biochemical Journal. 2000; 348: 359-365.
 49. Soni K, Kutian R. Effect of oral curcumin administration on serum peroxides and cholesterol levels in human volunteers. Indian J Physiol Pharmacol. 1992; 36: 273-275.
 50. Bihari SW, Singh AP, Tiwari M. In vivo investigation of the neuroprotective property of *Convolvulus pluricaulis* in scopolamine-induced cognitive impairments in Wistar rats. Indian journal of pharmacology. 2011; 43: 520.
 51. Kumar V, Potential medicinal plants for CNS disorders: An overview. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2006; 20: 1023-1035.
 52. Malik J, Karan M, Vasisht K. Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi. Pharmaceutical biology. 2011; 49: 1234-1242.
 53. Singh RH, Narsimhamurthy K, Singh G. Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Biogerontology. 2008; 9: 369-374.
 54. Sethiya NK, Nahata A, Mishra SH, Dixit VK. An update on Shankhpushpi, a cognition-boosting Ayurvedic medicine. Zhong xi yijie he xuebao= Journal of Chinese integrative medicine. 2009; 7: 1001-1022.
 55. Nahata A, Patil UK, Dixit VK. Effect of *Convolvuluspluricaulis* Choisy. On learning behaviour and memory enhancement activity in rodents. Natural product research. 2008; 22: 1472-1482.
 56. Sharma K, Bhatnagar M, Kulkarni SK. Effect of *Convolvulus pluricaulis* Choisy and *Asparagus racemosus* Willd on learning and memory in young and old mice: A comparative evaluation. 2010.
 57. Dubey GP, Pathak SR and Gupta BS. Combined effect of Brahmi (*Bacopamonniera*) and Shankhpushpi (*Convolvulus pluricaulis*) on cognitive functions. Pharmacopsychocol. 1994; 7: 249-251.
 58. Mukherjee PK, Kumar V, Kumar NS and Heinrich M. The Ayurvedic medicine *Clitoriaternatea*—from traditional use to scientific assessment. Journal of ethnopharmacology. 2008; 120: 291-301.
 59. Agarwal P, Alok S, Fatima A and Singh PP. Herbal remedies for neurodegenerative disorder (Alzheimer's disease): A Review. International Journal of Pharmaceutical Sciences and Research. 2013; 4: 3328.
 60. Chandrasekaran K, Mehrabian Z, Spinnewyn B, Drieu K, Fiskum G, et al. Neuroprotective effects of bilobalide, a component of the Ginkgo biloba extract (EGb 761), in gerbil global brain ischemia. Brain research. 2001; 922: 282-292.
 61. Shi C, Liu J, Wu F, Yew DT. Ginkgo biloba extract in Alzheimer's disease: From action mechanisms to medical practice. International Journal of Molecular Sciences. 2010; 11: 107-123.
 62. Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide induced toxicity: Involvement of its flavonoid constituents and protein kinase C. Journal of neurochemistry. 2000; 74: 2268-2277.
 63. Walesiuk A, Braszko JJ. Preventive action of Ginkgo biloba in stress-and corticosterone-induced impairment of spatial memory in rats. Phytomedicine. 2009; 16: 40-46.
 64. Nalini K, Aroor AR, Rao A, Karanth KS. Effect of *Centellaasiatica* fresh leaf aqueous extract on learning and memory and biogenic amine turnover in albino rats. Fitoterapia. 1992; 63: 231-238.
 65. Maurer K, Ihl R, Dierks T, Frölich L. Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. Journal of psychiatric research. 1997; 31: 645-655.
 66. Luo Y. Ginkgo biloba neuroprotection: Therapeutic implications in Alzheimer's disease. Journal of Alzheimer's Disease. 2001; 3: 401-407.
 67. Singh B, Rastogi RP. A reinvestigation of the triterpenes of *Centellaasiatica*. Phytochemistry. 1969; 8: 917-921.
 68. Dhanasekaran M, Holcomb LA, Hitt AR, Tharakan B, Porter JW, et al. *Centellaasiatica* extract selectively decreases amyloid β levels in hippocampus of Alzheimer's disease animal model. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2009; 23: 14-19.
 69. Gohil KJ, Patel JA, Gajjar AK. Pharmacological review on *Centellaasiatica*: A potential herbal cure-all. Indian journal of pharmaceutical sciences. 2010; 72: 546.
 70. Soumyanath Amala, Zhong YP, Henson E, Wadsworth T, Bishop J, et al. *Centellaasiatica* extract improves behavioral deficits in a mouse model of Alzheimer's disease: Investigation of a possible mechanism of action. International Journal of Alzheimer's Disease. 2012; 2012.
 71. Godkar PB, Gordon RK, Ravindran A, Doctor BP. *Celastruspaniculatus* seed oil and organic extracts attenuate hydrogen peroxide- and glutamate-induced injury in embryonic rat forebrain neuronal cells. Phytomedicine. 2006; 13: 29-36.
 72. Godkar P, Gordon RK, Ravindran A, Doctor BP. *Celastruspaniculatus* seed water soluble extracts protect cultured rat forebrain neuronal cells from hydrogen peroxide-induced oxidative injury. Fitoterapia. 2003; 74: 658-669.
 73. Bhanumathy M, Harish MS, Shivaprasad HN, Sushma G. Nootropic activity of *Celastruspaniculatus* seed. Pharmaceutical Biology. 2010; 48: 324-327.
 74. Kumar MHV, Gupta YK. Antioxidant property of *Celastruspaniculatus* Willd: A possible mechanism in enhancing cognition. Phytomedicine. 2002; 9: 302-311.
 75. Katekhaye S, Duggal S, Singh AP. An inside preview of nutritional

- and pharmacological profile of *Celastrus paniculatus*. *Int J Recent Adv Pharm Res*. 2011; 1: 19-24.
76. Divino da Rocha M, Pereira Dias Viegas F, Cristina Campos H, Carolina Nicastro P, Calve Fossaluzza P, et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. *CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders)*. 2011; 10: 251-270.
 77. Essa MM, Vijayan RK, Castellano Gonzalez G, Memon MA, Braidyn N, et al. Neuroprotective effect of natural products against Alzheimer's disease. *Neurochemical research*. 2012; 37: 1829-1842.
 78. Dastagir G, Rizvi MA. Review *Glycyrrhizaglabra L. (Licorice)* Pakistan Journal of Pharmaceutical Sciences. 2016; 29: 1727-1733.
 79. Ambavade SD, Kasture VS, Kasture SB, et al. Anxiolytic activity of *Glycyrrhizaglabra Linn*. *Journal of natural remedies*. 2001; 1: 130-134.
 80. Dhingra D, Parle M, Kulkarni SK. Memory enhancing activity of *Glycyrrhizaglabra* in mice. *Journal of ethnopharmacology*. 2004; 91: 361-365.
 81. Chakravarthi KK, Avadhani R. Beneficial effect of aqueous root extract of *Glycyrrhizaglabra* on learning and memory using different behavioral models: An experimental study. *Journal of natural science, biology, and medicine*. 2013; 4: 420.
 82. Tapia Rojas C, Cabezas Opazo F, Deaton CA, Vergara EH, Johnson GV, et al. It's all about tau. *Progress in neurobiology*. 2019; 175: 54-76.
 83. Joshi H, Parle M. *Nardostachys jatamansi* improves learning and memory in mice. *Journal of medicinal food*. 2006; 9: 113-118.
 84. Karkada G, Shenoy KB, Halahalli H, Karanth K. *Nardostachys jatamansi* extract prevents chronic restraint stress-induced learning and memory deficits in a radial arm maze task. *Journal of natural science, biology, and medicine*. 2012; 3: 125.
 85. Heo JH, Lee ST, Chu K, Oh MJ, Park HJ, et al. An open label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer's disease. *European Journal of Neurology*. 2008; 15: 865-868.
 86. Cho IH. Effects of *Panax ginseng* in neurodegenerative diseases. *Journal of ginseng research*. 2012; 36: 342.
 87. Kim HJ, Kim P, Shin CY. A comprehensive review of the therapeutic and pharmacological effects of ginseng and ginsenosides in central nervous system. *Journal of ginseng research*. 2013; 37: 8.
 88. Shin SJ, Nam Y, Park YH, Kim MJ, Lee E, et al. Therapeutic effects of non-saponin fraction with rich polysaccharide from Korean red ginseng on aging and Alzheimer's disease. *Free Radical Biology and Medicine*. 2021; 164: 233-248.
 89. Yang WT, Wang Y, Shi YH, Fu H, Xu Z, et al. Herbal compatibility of ginseng and rhubarb exerts synergistic neuroprotection in cerebral ischemia/reperfusion injury of rats. *Frontiers in physiology*. 2019; 10: 1174.
 90. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, et al. Tarenflurbil Phase 3 Study Group, Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. *Jama*. 2009; 302: 2557-2564.
 91. Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. 8-Hydroxyquinolines: A review of their metal chelating properties and medicinal applications. *Drug design, development and therapy*. 2013; 7: 1157.
 92. Hwang SH, Shin EJ, Shin TJ, Lee BH, Choi SH, et al. Gintonin, a ginseng-derived lysophosphatidic acid receptor ligand, attenuates Alzheimer's disease-related neuropathies: Involvement of non-amyloidogenic processing. *Journal of Alzheimer's Disease*. 2012; 31: 207-223.
 93. Kim HJ, Shin EJ, Lee BH, Choi SH, Jung SW, et al. Oral administration of gintonin attenuates cholinergic impairments by scopolamine, amyloid- β protein, and mouse model of Alzheimer's disease. *Molecules and cells*. 2015; 38: 796.
 94. Asgarpanah J, Kazemivash N. Phytochemistry and pharmacological properties of *Myristica fragrans* Hoyutt : A review. *African Journal of Biotechnology*. 2012; 11: 12787-12793.
 95. Narasimhan B, Dhake AS. Antibacterial principles from *Myristica fragrans* seeds. *Journal of medicinal food*. 2006; 9: 395-399.
 96. Parle M, Dhingra D, Kulkarni SK. Improvement of mouse memory by *Myristica fragrans* seeds. *Journal of medicinal food*. 2004; 7: 157-161.
 97. Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. *Behavioral neuroscience*. 1998; 112: 1199.
 98. Singh SK. Phytochemical analysis of leaf callus of *Bacopamonnieri L*. *Int J Sci Res Pub*. 2012; 2: 1-3.
 99. Russo A, Borrelli F. *Bacopamonniera*, a reputed nootropic plant: An overview. *Phytomedicine*. 2005; 12: 305-3
 100. Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb *Bacopamonnieri*. *Rejuvenation research*. 2013; 16: 313-326.
 101. Stough C, Downey LA, Lloyd J, Silber B, Redman S, et al. Examining the nootropic effects of a special extract of *Bacopamonniera* on human cognitive functioning: 90 day double blind placebo controlled randomized trial. *Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives*. 2008; 22: 1629-1634.
 102. Shinomol GK, Bharath MM. Exploring the role of "Brahmi" (*Bacopamonnieri* and *Centella asiatica*) in brain function and therapy. *Recent patents on endocrine, metabolic & immune drug discovery*. 2011; 5: 33-49.
 103. Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of *Bacopamonnieri* in Alzheimer's disease model. *Journal of ethnopharmacology*. 2010; 127: 26-31.
 104. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of *Bacopamonniera* in rat frontal cortex, striatum and hippocampus. *Phytotherapy Research*. 2000; 14: 174-179.
 105. Rubio J, Dang H, Gong M, Liu X, Chen SL, et al. Aqueous and hydroalcoholic extracts of Black Maca (*Lepidium meyenii*) improve scopolamine-induced memory impairment in mice. *Food and chemical toxicology*. 2007; 45: 1882-1890.
 106. Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine 1. *Acta Pharmacologica Sinica*. 2006; 27: 1-26.
 107. Rubio J, Qiong W, Liu X, Jiang Z, Dang H, et al. Aqueous extract of black maca (*Lepidium meyenii*) on memory impairment induced by ovariectomy in mice. *Evidence-Based Complementary and Alternative Medicine*. 2011; 2011.
 108. Pakade V, Cukrowska E, Chimuka L. Comparison of antioxidant activity of *Moringa oleifera* and selected vegetables in South Africa. *South African journal of science*. 2013; 109: 1-5.

109. Gangul R, Guha D. Alteration of brain monoamines & EEG wave pattern in rat model of Alzheimer's disease & protection by *Moringaoleifera*. *Indian Journal of medical research*. 2008; 128.
110. Obulesu M, Rao DM. Effect of plant extracts on Alzheimer's disease: An insight into therapeutic avenues. *Journal of neurosciences in rural practice*. 2011; 2: 056-061.
111. Vasudevan M, Parle M. Memory enhancing activity of *Anwala-churna* (*Emblicaofficinalis* Gaertn.): An Ayurvedic preparation. *Physiology & behaviour*. 2007; 91: 46-54.
112. Ramachandran S, Sanjay AS, Dhanaraju MD. Antiamnesic effect of Piracetam potentiated with *Emblicaofficinalis* and *Curcuma longa* in aluminium induced neurotoxicity of Alzheimer's disease. *Int J Adv Res*. 2013; 1: 185-196.
113. Mahrous R, Ghareeb DA, Fathy HM, EL Khair RMA, Omar AA. The protective effect of Egyptian *Withaniasomnifera* against Alzheimer's. *Med. Aromat Plants*. 2017; 6: 2167-0412.
114. Liu QF, Jeong H, Lee JH, Hong YK, Oh Y, et al. *Coriandrumsativum* suppresses A β 42-induced ROS increases, glial cell proliferation, and ERK activation. *The American journal of Chinese medicine*. 2016; 44: 1325-1347.
115. Nie L, Xia J, Li H, Zhang Z, Yang Y, et al. Ginsenoside Rg1 ameliorates behavioral abnormalities and modulates the hippocampal proteomic change in triple transgenic mice of Alzheimer's disease. *Oxidative medicine and cellular longevity*. 2017; 2017.
116. Song JH, Lee JW, Shim B, Lee CY, Choi S, et al. Glycyrrhizin alleviates neuroinflammation and memory deficit induced by systemic lipopolysaccharide treatment in mice. *Molecules*. 2013; 18: 15788-15803.
117. Lee YK, Yuk DY, Kim TI, Kim YH, Kim KT, et al. Protective effect of the ethanol extract of *Magnolia officinalis* and 4-O-methylhonokiol on scopolamine-induced memory impairment and the inhibition of acetylcholinesterase activity. *Journal of natural medicines*, 2009; 63: 274-282.
118. Hoi CP, Ho YP, Baum L, Chow AH. Neuroprotective effect of honokiol and magnolol, compounds from *Magnolia officinalis*, on beta amyloid induced toxicity in PC12 cells. *Phytotherapy Research*. 2010; 24: 1538-1542.
119. Gharibi A, Khalili M, Kiasalari Z, Hoseinirad M. The effect of *Zingiberofficinalis* L. on learning and memory in rats. *J Bas Clin Pathophysiol*. 2013; 2: 2013-2014.
120. Farokhnia M, Shafiee Sabet M, Iranpour N, Gougol A, Yekehtaz H, et al. Comparing the efficacy and safety of *Crocus sativus* L. with memantine in patients with moderate to severe Alzheimer's disease: A double blind randomized clinical trial. *Human Psychopharmacology: Clinical and Experimental*. 2014; 29:351-359. by ovariectomy in mice. *Evidence-Based Complementary and Alternative Medicine*, 2011.
121. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, et al. A 22-week, multicenter, randomized, double-blind controlled trial of *Crocus sativus* in the treatment of mild-to-moderate Alzheimer's disease. *Psychopharmacology*. 2010; 207: 637-643.
122. Yoo DY, Nam Y, Kim W, Yoo KY, Park J, et al. Effects of *Ginkgo biloba* extract on promotion of neurogenesis in the hippocampal dentate gyrus in C57BL/6 mice. *Journal of Veterinary Medical Science*. 2010; 1008230321-1008230321.
123. Khojah H, Edrada Ebel R. Identification of bioactive metabolites from *Ficuscarica* and their neuroprotective effects of Alzheimer's disease. *International Journal of Medical and Health Sciences*. 2017; 11: 2158.
124. Subash S, Essa MM, Braidy N, Al-Jabri A, Vaishnav R, et al. Consumption of fig fruits grown in Oman can improve memory, anxiety, and learning skills in a transgenic mice model of Alzheimer's disease. *Nutritional neuroscience*. 2016; 19: 475-483.
125. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. *Journal of Neuroscience*. 2001; 21: 8370-8377.
126. Jeong HY, Kim JY, Lee HK, Ha DT, Song KS, et al. Leaf and stem of *Vitisamurensis* and its active components protect against amyloid β protein (25–35)-induced neurotoxicity. *Archives of pharmacological research*. 2010; 33: 1655-1664.
127. Vasudevan M, Parle M. Pharmacological actions of *Thespesia-populnea* relevant to Alzheimer's disease. *Phytomedicine*. 2006; 13: 677-687.
128. Choi SJ, Lee JH, Heo HJ, Cho HY, Kim HK, et al. *Punicagranatum* protects against oxidative stress in PC12 cells and oxidative stress-induced Alzheimer's symptoms in mice. *Journal of medicinal food*. 2011; 14: 695-701.
129. Lee CL, Pan TM. Red mold fermented products and Alzheimer's disease: A review. *Applied microbiology and biotechnology*. 2011; 91: 461-469.
130. Abdul Manap AS, Vijayabalan S, Madhavan P, Chia YY, Arya A, et al. Bacopamonnieri, a neuroprotective lead in Alzheimer disease: A review on its properties, mechanisms of action, and preclinical and clinical studies. *Drug target insights*. 2019; 13: 1177392819866412.
131. Agarwa P, Sharma B, Fatima A, Jain SK. An update on Ayurvedic herb *Convolvulus pluricaulis Choisy*. *Asian Pacific journal of tropical biomedicine*. 2014; 4: 245-252.
132. Rahman H, Muralidharan P, Anand M. Inhibition of AChE and antioxidant activities are probable mechanism of *Nardostacys-jatamansi* DC in sleep deprived Alzheimer's mice model. *Int J Pharm Tech Res*. 2011; 3: 1807-1816.
133. Gray NE, Harris CJ, Quinn JF, Soumyanath A. *Centellaasiatica* modulates antioxidant and mitochondrial pathways and improves cognitive function in mice. *Journal of ethnopharmacology*. 2016; 180: 78-86.
134. Bhatia A, Bharti SK, Tripathi T, Mishra A, Sidhu OP, et al. Metabolic profiling of *Commiphorawightii* (guggul) reveals a potential source for pharmaceuticals and nutraceuticals. *Phytochemistry*. 2015; 110: 29-36.
135. Kosaraju J, Chinni S, Roy PD, Kannan E, Antony AS, et al. Neuroprotective effect of *Tinosporacordifolia* ethanol extract on 6-hydroxy dopamine induced Parkinsonism. *Indian Journal of Pharmacology*. 2014; 46: 176.
136. Sankhala LN, Saini RK, Saini BS. A review on chemical and biological properties of *Tinosporacordifolia*. *International Journal of Medicinal and Aromatic Plants*. 2012; 2: 340-344.
137. Lin SH, Chou ML, Chen WC, Lai YS, Lu KH, et al. A medicinal herb, *Melissa officinalis* L. ameliorates depressive-like behavior of rats in the forced swimming test via regulating the serotonergic neurotransmitter. *Journal of ethnopharmacology*. 2015; 175: 266-272.
138. Beheshti S, Shahmoradi B. Therapeutic effect of *Melissa officinalis* in an amyloid- β rat model of Alzheimer's disease. *Journal of Herbmed Pharmacology*. 2018; 7.
139. Rao MK, Rao MS, Rao GS. Treatment with *Centellaasiatica* (Linn) fresh leaf extract enhances learning ability and memory retention power in rats. *Neurosciences Journal*. 2007; 12: 236-241.